FDB agrees to manufacture Argenx’s antibody therapy efgartigimod
Under the agreement, FDB will provide drug substance manufacturing of efgartigimod at its large-scale biomanufacturing facility in Hillerød,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
28 Oct 22
Under the agreement, FDB will provide drug substance manufacturing of efgartigimod at its large-scale biomanufacturing facility in Hillerød,…
09 Sep 22
The collaboration will combine AstraZeneca’s expertise in RNA therapeutics with Gatehouse Bio’s capabilities in small RNA compounds to…
01 Aug 22
Under the new agreement with the US government, the biotechnology company will receive up to $1.74bn for 66…
13 Jul 22
GenScript ProBio will support ACT therapeutics’ CAR-T Platform (ACT platform), an immune cell-based cell and gene therapy technology…
12 Jul 22
Ionis will receive $55m from Roche, in exchange for licensing IONIS-FB-LRx and achieving a development milestone in the…
04 Jul 22
The company is entitled to receive a settlement fee of $55m and will assume responsibility for the marketing…
30 May 22
ViiV Healthcare and MPP are actively negotiating on terms of a voluntary licensing agreement, which would help widen…
11 Mar 22
Xcellomics programme was created by the two Oxford-based institutions to advance the early-stage drug discovery research by academic…
02 Mar 22
Alexion will obtain an exclusive licence to develop, manufacture and market NI006, and will pay $30m upfront, and…
16 Feb 22
ImmunoGen will receive $13m in upfront payment for initial targets and is eligible to receive an additional $32.5m…